2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
April 13, 2017Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer
— New CFO Is an Established Leader and Healthcare Industry Veteran — BRISBANE, Calif.--(BUSINESS WIRE)--Apr. 13, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the appointment of Eric Bjerkholt as Chief Financial Officer. Mr. Bjerkholt joins Aimmune from Sunesis Pharmaceuticals, Inc., where, over 13 years with the company, his role as CFO expanded to oversee multiple aspects of governance, corporate relations, and other ... 
 
March 15, 2017Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
— Company Began 2017 with Approximately $283 Million in Cash and Investments, Sufficient to Support Current Development Plans through Regulatory Submissions — — Conference Call and Webcast Today at 8:00 a.m. ET — BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 15, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food... 
 
March 8, 2017Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017
- Conference Call and Webcast to Follow at 8:00 a.m. ET/ 5:00 a.m. PT - BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its financial results for the fourth quarter and full year 2016 will be released on Wednesday, March 15, 2017, before U.S. markets open. At 8:00 a.m. Eastern Time / 5:00 a.m. ... 
 
March 6, 2017Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
— Unique Dataset of Double-Blind, Placebo-Controlled Food Challenges from Phase 3 PALISADE North American Screened Population Is Largest Ever Collected on Peanut-Allergic Patients and Provides Valuable Insights for Future Study — — 95% Adherence to Daily At-Home AR101 Dosing in Blinded Phase 2 Study — BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 6, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company develop... 
 
March 1, 2017Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March
BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 1, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a company overview at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017, at 10:00 a.m. Eastern Time and at th... 
 
February 27, 2017Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 27, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that new clinical data on AR101 will be presented during poster sessions on Monday, March 6, at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place Mar... 
 
February 16, 2017Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
— AR101 Program to Initially Address Urgent Unmet Need of Peanut-Allergic Patients Ages 4-17, Consistent with Breakthrough Therapy Designation — — Potential BLA Filing to Include Safety Database of 600 Patients, Achievable with Current Phase 3 Program — — Conference Call Today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time — BRISBANE, Calif.--(BUSINESS WIRE)--Feb. 16, 2017-- Aimmune Therapeutics, Inc. (Nasdaq... 
 
January 4, 2017Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
Presentation on Wednesday, January 11, 2017, at 5:00 p.m. Pacific Time BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 4, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present a company overview at the 35th Annual J.P. Morgan Healthcare Conferen...